secwatch.observer — SEC 8-K summary
======================================

Issuer:     LISATA THERAPEUTICS, INC. (LSTA)
CIK:        0000320017
Form:       8-K
Filed at:   2024-12-03T23:59:59+00:00
Accession:  0000320017-24-000061
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Lisata Therapeutics licenses certepetide to Kuva Labs for solid tumor imaging
-----------------------------------------------------------------------------

- Upfront cash license fee of $1.0M payable over 12 months in four installments.
- Development milestones up to $1.5M; commercial milestones up to $17.5M; 5% royalty on net sales.
- Kuva assumes full R&D and commercialization costs; Lisata to supply certepetide for clinical and commercial use.
- Partnership combines Lisata's certepetide with Kuva's NanoMark imaging technology for solid tumors.
- Agreement effective November 30, 2024; Kuva may terminate on 60-day notice.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/320017/000032001724000061/0000320017-24-000061-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/320017/000032001724000061/clbs-20241203.htm
  HTML page:      https://secwatch.observer/filing/0000320017-24-000061

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer